PCSK9 Inhibitor Therapy: Payer Authorizations in the 12 Months Following FDA Approval

- Less than half of patients prescribed PCSK9 inhibitor therapy were approved by their insurance payer
  - 47% Approved
  - 53% Rejected

- Payer type was the most significant factor associated with approval

- 35% of approved patients abandoned the medication
  - Their out-of-pocket cost was more than twice as much as for patients who purchased the drug

Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir LR, Yeh RW. Circulation October 2017